Law of Averages

Anderson, Brian N.
May 2010
Best's Review;May2010, Vol. 111 Issue 1, p83
Trade Publication
The article discusses the change in calculating the benchmark average wholesale price for prescription drugs in the U.S. It states that a federal litigation leads to a different drug pricing that the health industry hopes to adapt. However, confusion as to the implementation of pricing changes is seen and payors working through pharmacy benefit managers need to examine pricing procedures and adjust to the changes while maintaining mutual trust and integrity.


Related Articles

  • Financial Effects of Pharmaceutical Price Regulation on R&D Spending by EU versus US Firms. Golec, Joseph; Vernon, John A. // PharmacoEconomics;2010, Vol. 28 Issue 8, p615 

    EU countries closely regulate pharmaceutical prices, whereas theUS does not. This paper shows how price constraints affect the profitability, stock returns and R&D spending of EU and US firms. Compared with EU firms, US firms are more profitable, earn higher stock returns and spend more on R&D....

  • Determining Process Quality Metrics for CMOs. Lusczakoski, Kate DeRoche // BioPharm International;Jun2012, Vol. 25 Issue 6, p14 

    The article focuses on the process quality metrics for contract manufacturing organizations (CMOs) in the U.S. bio/pharmaceutical industry. It notes the two important manufacturing trends which are the increasing adoption of quality-by-design (QbD) and the increase use of CMOs. The best...

  • 3 controlled bulk drugs prices cut.  // Chemical Business;Oct95, Vol. 9 Issue 3, p30 

    Reports on the price cut of the three controlled bulk drugs, ranitidine, doxycycline and spironolactone by a notification issued on September 7, 1995 based on the recommendations made by the Bureau of Industrial Costs and Prices (BICP). Falling of prices of several imported inputs used in the...

  • France, Italy take tough stance on rising drug costs.  // PharmacoEconomics & Outcomes News;6/12/2010, Issue 605, p15 

    The article examines the initiatives of the French and Italian governments to address the increasing cost of drugs.

  • Pricing not right--yet. Conlan, Michael F. // Drug Topics;7/7/97, Vol. 141 Issue 13, p48 

    Provides information on governments plans to implement discounted drugs to health care facilities. Financial information on pharmaceutical products; Information on the Federal Supply Schedule (FSS). INSET: Strange Rx stories, by Guy Reeser..

  • Uniform pharma pricing.  // Chemical Business;Aug95, Vol. 9 Issue 1, p27 

    Reports that the Indian government has issued notification amending the drug price control order (DPCO) 1995, which will bring uniformity in price marking. Details.

  • To charge or not to charge?  // Nursing Standard;4/15/2009, Vol. 23 Issue 32, p28 

    Readers respond to a question of whether Great Britain's National Health Service should eliminate prescription drug charges for everyone.

  • Prices of 13 bulk drugs to be cut to pass on duty benefit.  // Chemical Business;Jul95, Vol. 8 Issue 12, p85 

    Reports on the decision of the government of India to reduce the prices of 13 bulk drugs. Minister for Chemicals and Fertilizers Ram Lakhan Singh Yadav's order for a review of the prices; Reduction in the maximum duty on chemicals.

  • IV fluids price rise curbed. Aiyar, Sharda // Chemical Business;May96, Vol. 9 Issue 10, p63 

    Reports on India's restrictions on prices of intravenous (IV) fluids. Attempt to bring IV fluids under the authority of the Drugs order 1995.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics